AIM ImmunoTech's Financial Woes Deepen Amid Delisting, Cash Burn

TL;DR

**AIM is bleeding cash, delisted, and facing a going concern warning; this stock is a speculative gamble at best.**

AI Summary

AIM ImmunoTech Inc. reported a significant increase in net loss for the six months ended June 30, 2025, reaching $6.499 million, compared to $7.653 million for the same period in 2024. Total revenues decreased by 54.4% to $41,000 in H1 2025 from $90,000 in H1 2024, primarily from clinical treatment programs. The company's cash and cash equivalents plummeted to $476,000 as of June 30, 2025, from $1.701 million at December 31, 2024, and total current assets fell from $4.176 million to $1.025 million. A reverse stock split of 1-for-100 was implemented on June 12, 2025, to address NYSE American listing deficiencies, but the stock was delisted on April 4, 2025, and now trades on the Pink Open Market under 'AIMI'. The company faces substantial doubt about its ability to continue as a going concern, with a stockholders' deficit of ($6.5) million as of June 30, 2025, far below the NYSE American's $6.0 million requirement. Research and development expenses decreased to $2.254 million in H1 2025 from $3.096 million in H1 2024, while general and administrative expenses also saw a substantial reduction to $4.032 million from $6.406 million. The company is prioritizing clinical trials for Ampligen in pancreatic cancer and exploring its use in other cancers, viral diseases, ME/CFS, and as a vaccine adjuvant.

Why It Matters

AIM ImmunoTech's precarious financial position, marked by a substantial stockholders' deficit of ($6.5) million and a significant drop in cash to $476,000, signals extreme risk for investors. The delisting from NYSE American to the Pink Open Market under 'AIMI' severely impacts liquidity and investor confidence, making it difficult to raise necessary capital. For employees, the going concern warning raises job security concerns, while customers and partners may question the long-term viability of Ampligen's development. In a competitive immuno-pharma landscape, AIM's inability to secure stable funding could halt critical clinical trials and prevent its flagship product, Ampligen, from reaching market potential.

Risk Assessment

Risk Level: high — The company explicitly states 'substantial doubt regarding the Company's ability to continue as a going concern' due to incurred losses, negative operating cash flow, and a working capital deficit. Its stockholders' deficit of ($6.5) million as of June 30, 2025, is significantly below the NYSE American's $6.0 million minimum requirement, leading to delisting on April 4, 2025.

Analyst Insight

Investors should avoid AIM ImmunoTech due to severe liquidity issues, a going concern warning, and delisting from the NYSE American. The company's ability to fund ongoing clinical trials for Ampligen is highly questionable, making it a high-risk, speculative investment.

Financial Highlights

debt To Equity

N/A

revenue

$41,000

operating Margin

N/A

total Assets

$4,129,000

total Debt

$10,675,000

net Income

($6,499,000)

eps

($8.88)

gross Margin

N/A

cash Position

$476,000

revenue Growth

-54.4%

Revenue Breakdown

Key Numbers

• $6.499M — Net Loss (for the six months ended June 30, 2025, compared to $7.653M in H1 2024)
• $41K — Total Revenues (for the six months ended June 30, 2025, a 54.4% decrease from $90K in H1 2024)
• $476K — Cash and Cash Equivalents (as of June 30, 2025, down from $1.701M at December 31, 2024)
• ($6.5M) — Stockholders' Deficit (as of June 30, 2025, below NYSE American's $6.0M minimum)
• 1-for-100 — Reverse Stock Split Ratio (implemented on June 12, 2025)
• $2.254M — Research and Development Expenses (for the six months ended June 30, 2025, down from $3.096M in H1 2024)
• $4.032M — General and Administrative Expenses (for the six months ended June 30, 2025, down from $6.406M in H1 2024)
• $1.025M — Total Current Assets (as of June 30, 2025, down from $4.176M at December 31, 2024)

Key Players & Entities

• AIM ImmunoTech Inc. (company) — registrant
• Ampligen (company) — flagship product
• NYSE American (regulator) — stock exchange from which AIM was delisted
• Streeterville Capital LLC (company) — lender for unsecured promissory note
• FDA (regulator) — Food and Drug Administration
• EMA (regulator) — European Medicines Agency
• AstraZeneca (company) — partner for FluMist vaccine adjuvant
• Ocala, Florida (person) — company headquarters location

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company faces substantial doubt about its ability to continue as a going concern due to a significant stockholders' deficit of ($6.5) million as of June 30, 2025, which is substantially below the NYSE American's minimum requirement of $6.0 million. This, coupled with a sharp decline in cash and cash equivalents to $476,000 from $1.701 million, highlights severe financial distress.
• Delisting and Trading on Pink Sheets [high — regulatory]: AIM ImmunoTech Inc. was delisted from the NYSE American on April 4, 2025, due to listing deficiencies, specifically a stockholders' deficit below the required threshold. The stock now trades on the Pink Open Market under 'AIMI', indicating a significant downgrade in its trading venue and potential investor confidence.
• Plummeting Cash Reserves [high — financial]: Cash and cash equivalents have drastically decreased to $476,000 as of June 30, 2025, a significant drop from $1.701 million at December 31, 2024. This severe reduction in liquidity, alongside a fall in total current assets from $4.176 million to $1.025 million, raises concerns about the company's short-term operational funding.
• Declining Revenue [medium — financial]: Total revenues for the six months ended June 30, 2025, decreased by 54.4% to $41,000 from $90,000 in the same period of 2024. This substantial revenue decline, primarily from clinical treatment programs, indicates a weakening revenue stream.
• Reduced R&D and G&A Spending [medium — operational]: While R&D expenses decreased to $2.254 million from $3.096 million and G&A expenses were reduced to $4.032 million from $6.406 million, these cuts may reflect a constrained operational capacity rather than efficiency gains, especially given the going concern issues.
• FDA Approval Status [medium — regulatory]: Ampligen has not been approved by the FDA for marketing in the United States, although it is approved in Argentina for Chronic Fatigue Syndrome. This lack of US FDA approval limits its market potential and revenue generation capabilities within its primary target market.

Industry Context

AIM ImmunoTech operates in the immuno-pharma sector, focusing on novel therapeutics for cancer and viral diseases. The industry is highly competitive and capital-intensive, with significant R&D investment required for drug development and regulatory approval. Companies in this space often face challenges in securing funding, navigating complex clinical trials, and achieving FDA approval, especially for novel mechanisms of action like Ampligen's dsRNA platform.

Regulatory Implications

The delisting from the NYSE American and subsequent trading on the Pink Open Market highlight significant regulatory and compliance challenges. The company's failure to meet listing requirements, particularly the stockholders' equity threshold, indicates a high level of regulatory scrutiny and potential investor risk. Continued focus on FDA approval pathways for Ampligen remains critical for future market access and viability.

What Investors Should Do

1. Monitor cash burn rate and future financing activities.
2. Evaluate progress and catalysts in Ampligen clinical trials.
3. Assess the implications of trading on the Pink Open Market.

Key Dates

• 2025-06-12: Reverse Stock Split — Implemented a 1-for-100 reverse stock split to attempt to meet NYSE American listing requirements, though it ultimately did not prevent delisting.
• 2025-04-04: Delisting from NYSE American — The company's common stock was delisted from the NYSE American, indicating failure to meet listing standards and a significant reduction in market accessibility and prestige.
• 2025-06-30: End of Q2 2025 — Reported a stockholders' deficit of ($6.5) million and cash of $476,000, underscoring severe financial challenges and going concern issues.
• 2024-06-30: End of Q2 2024 — Reported a stockholders' deficit of ($6.1) million and cash of $3,554,000, showing a worsening financial position compared to the prior year.

Glossary

Stockholders' Deficit

A situation where a company's total liabilities exceed its total assets, resulting in a negative net worth for shareholders. (AIM ImmunoTech has a significant stockholders' deficit of ($6.5) million, indicating negative equity and raising concerns about its financial stability and ability to continue as a going concern.)

Going Concern

An accounting assumption that a business will continue to operate for the foreseeable future, typically at least 12 months from the reporting date. (The company's financial condition, including its substantial deficit and low cash, has led to substantial doubt about its ability to continue as a going concern.)

Reverse Stock Split

A corporate action to reduce the number of outstanding shares of a company by consolidating existing shares into fewer, proportionally more valuable shares. (AIM ImmunoTech implemented a 1-for-100 reverse stock split on June 12, 2025, in an attempt to address listing deficiencies, though it did not prevent delisting.)

Pink Open Market

A quotation service for over-the-counter (OTC) securities that are not listed on major exchanges like NYSE or Nasdaq. It is known for less stringent listing requirements. (AIM ImmunoTech's stock now trades on the Pink Open Market after being delisted from the NYSE American, signifying a lower tier of market trading.)

Ampligen (rintatolimod)

A double-stranded RNA (dsRNA) molecule developed by AIM ImmunoTech for various cancers, viral diseases, and immune-deficiency disorders. (This is AIM's flagship product, currently undergoing clinical trials for pancreatic cancer and other indications, representing the core of the company's R&D efforts.)

Year-Over-Year Comparison

Compared to the six months ended June 30, 2024, AIM ImmunoTech has seen a significant decrease in total revenues, falling 54.4% to $41,000 from $90,000. While the net loss has narrowed slightly to $6.499 million from $7.653 million, this is largely due to substantial reductions in operating expenses, with R&D down to $2.254 million from $3.096 million and G&A down to $4.032 million from $6.406 million. The most alarming change is the drastic reduction in cash and cash equivalents, which plummeted to $476,000 from $1.701 million, and a worsening stockholders' deficit, highlighting a deteriorating financial position despite cost-cutting measures.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share AIM NYSE American Indic
• $250,000 — ement allows the Lender to redeem up to $250,000 per calendar month beginning in August

Filing Documents

• form10-q.htm (10-Q) — 1138KB
• ex10-1.htm (EX-10.1) — 16KB
• ex31-1.htm (EX-31.1) — 19KB
• ex31-2.htm (EX-31.2) — 18KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• 0001493152-25-011986.txt ( ) — 6026KB
• aimi-20250630.xsd (EX-101.SCH) — 44KB
• aimi-20250630_cal.xml (EX-101.CAL) — 53KB
• aimi-20250630_def.xml (EX-101.DEF) — 213KB
• aimi-20250630_lab.xml (EX-101.LAB) — 363KB
• aimi-20250630_pre.xml (EX-101.PRE) — 294KB
• form10-q_htm.xml (XML) — 899KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 Commission File Number: 001-27072 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 52-0845822 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 2117 SW Highway 484 , Ocala FL 34473 (Address of principal executive offices) (Zip Code) (352) 448-7797 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, par value $0.001 per share AIM NYSE American Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files). Yes No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definition of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No 2,708,688 shares of common stock were outstanding, and no shares of series B preferred stock were outstanding as of August 12, 2025. PART I- FINANCIAL INFORMATION ITEM 1 : Financial Statements AIM IMMUNOTECH INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (in thousands, except for share and per share amounts) (Unaudited June 30, 2025 and Audited December 31, 2024) June 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 476 $ 1,701 Marketable investments 359 2,276 Prepaid expenses and other current assets 190 199 Total current assets 1,025 4,176 Property and equipment, net 89 108 Right of use asset, net 496 618 Patent and trademark rights, net 2,168 2,594 Other assets 351 1,112 Total assets $ 4,129 $ 8,608 LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities: Accounts payable $ 7,297 $ 6,383 Accrued expenses 573 606 Current portion of operating lease liability 233 239 Current portion of note payable, net 2,290 2,307 Total current liabilities 10,393 9,535 Long-term liabilities: Operating lease liability 282 395 Total liabilities 10,675 9,930 Commitments and contingencies (Notes 13 and 14) - - Stockholders' deficit: Series A Junior Participating Preferred Stock, $ 0.001 par value, 4,000,000 and 250,000 shares authorized as of June 30, 2025, and December 31, 2024, respectively; issued and outstanding – none — — Series B Convertible Preferred Stock, stated value $ 1,000 per share, 10,000 shares authorized; as of June 30, 2025, and December 31, 2024, respectively; issued and outstanding – none — — Preferred Stock, value — — Common Stock, $ 0.001 par value, authorized shares - 350,000,000 ; issued and outstanding shares 764,188 and 655,263 as of June 30, 2025 and December 31, 2024, respectively 1 1 Additional paid-in capital 426,780 425,505 Accumulated deficit ( 433,327 ) ( 426,828 ) Total stockholders' deficit ( 6,546 ) ( 1,322 ) Total liabilities and stockholders' deficit $ 4,129 $ 8,608 See accompanying notes to consolidated financial statements. 2 AIM IMMUNOTECH INC. AND SUBSIDIARIES Consolidated (in thousands, except share and per share data) (Unaudited) 2025 2024 2025 2024 Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 Revenues: Clinical treatment programs - US $ 25 $ 50 $ 41 $ 90 Total Revenues 25 50 41 90 Costs and Expenses: Production costs 10 8 20 16 Research and

View Full Filing

View this 10-Q filing on SEC EDGAR